

APPLICANT (stamp or sticker acceptable) **PATIENT NHI:** **REFERRER** Reg No:

Reg No: First Names: First Names:

Name: Surname: Surname:

Address: DOB: Address:

..... Address:

.....

Fax Number: Fax Number:

Nivolumab

Initial application — unresectable or metastatic melanoma

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

| | |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> | The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV |
| and | |
| <input type="checkbox"/> | Baseline measurement of overall tumour burden is documented clinically and radiologically |
| and | |
| <input type="checkbox"/> | The individual has ECOG performance 0-2 |
| and | |
| <input type="checkbox"/> | The individual has not received funded pembrolizumab |
| or | |
| <input type="checkbox"/> | The individual has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance |
| and | |
| <input type="checkbox"/> | The cancer did not progress while the individual was on pembrolizumab |
| and | |
| <input type="checkbox"/> | The individual has been diagnosed in the metastatic or unresectable stage III or IV setting |
| or | |
| <input type="checkbox"/> | The individual did not receive treatment in the perioperative setting with a PD-1/PD-L1 inhibitor |
| or | |
| <input type="checkbox"/> | The individual received treatment in the perioperative setting with a PD-1/PD-L1 inhibitor |
| and | |
| <input type="checkbox"/> | The individual did not experience disease recurrence while on treatment with that PD-1/PD-L1 inhibitor |
| and | |
| <input type="checkbox"/> | The individual did not experience disease recurrence within six months of completing perioperative treatment with a PD-1/PD-L1 inhibitor |

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

| | | |
|------------------------------------------------|---------------------------|-------------------------------|
| APPLICANT (stamp or sticker acceptable) | PATIENT NHI: | REFERRER Reg No: |
| Reg No: | First Names: | First Names: |
| Name: | Surname: | Surname: |
| Address: | DOB: | Address: |
| | Address: | |
| | | |
| Fax Number: | | Fax Number: |

Nivolumab - *continued*

Renewal — unresectable or metastatic melanoma, less than 24 months on treatment

Current approval Number (if known):.....

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- The individual's disease has had a complete response to treatment
- or
- The individual's disease has had a partial response to treatment
- or
- The individual has stable disease

and

- Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

or

- The individual has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression
- and
- The individual has signs of disease progression
- and
- Disease has not progressed during previous treatment with nivolumab

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

| | | |
|------------------------------------------------|---------------------------|-------------------------------|
| APPLICANT (stamp or sticker acceptable) | PATIENT NHI: | REFERRER Reg No: |
| Reg No: | First Names: | First Names: |
| Name: | Surname: | Surname: |
| Address: | DOB: | Address: |
| | Address: | |
| | | |
| Fax Number: | | Fax Number: |

Nivolumab - *continued*

Renewal — unresectable or metastatic melanoma, more than 24 months on treatment

Current approval Number (if known):.....

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

| | |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> | The individual has been on treatment for more than 24 months |
| and | |
| <input type="checkbox"/> | The individual's disease has had a complete response to treatment |
| or | |
| <input type="checkbox"/> | The individual's disease has had a partial response to treatment |
| or | |
| <input type="checkbox"/> | The individual has stable disease |
| and | |
| <input type="checkbox"/> | Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period |
| or | |
| <input type="checkbox"/> | The individual has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression |
| and | |
| <input type="checkbox"/> | The individual has signs of disease progression |
| and | |
| <input type="checkbox"/> | Disease has not progressed during previous treatment with nivolumab |

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable) **PATIENT NHI:** **REFERRER** Reg No:

Reg No: First Names: First Names:

Name: Surname: Surname:

Address: DOB: Address:

..... Address:

.....

Fax Number: Fax Number:

Nivolumab - continued

Initial application — renal cell carcinoma, first line

Applications from any relevant practitioner. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

Patient is currently on treatment with nivolumab and met all remaining criteria prior to commencing treatment

or

The patient has metastatic renal cell carcinoma

and

The patient is treatment naive

and

The patient has ECOG performance status 0-2

and

The disease is predominantly of clear cell histology

and

The patient has sarcomatoid histology

or

Haemoglobin levels less than the lower limit of normal

or

Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L)

or

Neutrophils greater than the upper limit of normal

or

Platelets greater than the upper limit of normal

or

Interval of less than 1 year from original diagnosis to the start of systemic therapy

or

Karnofsky performance score of less than or equal to 70

and

Nivolumab is to be used in combination with ipilimumab for the first four treatment cycles at a maximum dose of 3 mg/kg

and

Nivolumab is to be used as monotherapy at a maximum maintenance dose of 240 mg every 2 weeks (or equivalent)

Initial application — Renal cell carcinoma, second line

Applications from any relevant practitioner. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

Patient has metastatic renal-cell carcinoma

and

The disease is of predominant clear-cell histology

and

Patient has ECOG performance status 0-2

and

Patient has documented disease progression following one or two previous regimens of antiangiogenic therapy

and

Patient has not previously received a funded immune checkpoint inhibitor

and

Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

| | | |
|------------------------------------------------|---------------------------|-------------------------------|
| APPLICANT (stamp or sticker acceptable) | PATIENT NHI: | REFERRER Reg No: |
| Reg No: | First Names: | First Names: |
| Name: | Surname: | Surname: |
| Address: | DOB: | Address: |
| | Address: | |
| | | |
| Fax Number: | | Fax Number: |

Nivolumab - *continued*

Renewal — Renal cell carcinoma

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- Patient's disease has had a complete response to treatment
- or
- Patient's disease has had a partial response to treatment
- or
- Patient has stable disease

and

No evidence of disease progression

and

Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz